{
    "nct_id": "NCT06857942",
    "official_title": "A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice",
    "inclusion_criteria": "* Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)\n* Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to <30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).\n* Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.\n* Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have currently received ixekizumab for more than 4 months or less than 2 months.\n* Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.\n* Are currently enrolled in any other clinical study.\n\nOther exclusions\n\n* Have a known hypersensitivity to tirzepatide or to any of its component.\n* Have a personal or family history of medullary thyroid cancer.\n* Have multiple endocrine neoplasia type 2.\n* Have type I diabetes mellitus.\n* Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).\n* Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.\n* Have a history of ketoacidosis or hyperosmolar state/coma.\n* Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.\n* Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.",
    "miscellaneous_criteria": ""
}